Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will report fourth quarter and full year 2025 financial results on February 24, 2026 after the close of U.S. markets. Management will host a live webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss results and provide a business and financial update.

Interested parties may register in advance via the Investors section of the Jazz Pharmaceuticals website. A replay will be posted to the investor site for on‑demand access.

News Market Reaction – JAZZ

+0.37%

+0.37% Session close to close

In the Feb 11 session, JAZZ gained 0.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Jazz’s fourth quarter and full year 2025 results for February 24, 2026 w...

Analysis

This announcement schedules Jazz’s fourth quarter and full year 2025 results for February 24, 2026 with a webcast at 4:30 p.m. ET. It adds to a steady flow of recent clinical, corporate, and investor events. With shares trading between the 95.49 52-week low and 182.99 high and above the 134.21 200-day MA, investors may focus on how upcoming results relate to previously communicated guidance and the performance of key growth assets.

Key Figures

Earnings date: February 24, 2026 Webcast time ET: 4:30 p.m. ET Webcast time GMT: 9:30 p.m. GMT +1 more

4 metrics

Earnings date February 24, 2026 Q4 and full-year 2025 results release after U.S. market close

Webcast time ET 4:30 p.m. ET Management webcast to discuss Q4 and 2025 results

Webcast time GMT 9:30 p.m. GMT Same earnings results webcast in GMT

Registration lead time 15 minutes Recommended minimum early registration before scheduled webcast

Historical Context

5 past events · Latest: Jan 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 15	Distribution announcement	Neutral	+0.2%	Quarterly cash distribution declaration and key record/payment dates.
Jan 08	Executive appointment	Positive	+0.6%	Appointment of Thomas Riga as Chief Business Officer with deal-making track record.
Jan 06	Clinical trial results	Positive	-4.2%	Positive Phase 3 HERIZON-GEA-01 results for Ziihera in HER2+ GEA.
Dec 17	Investor conferences	Neutral	-2.8%	Planned webcasts for clinical updates and J.P. Morgan conference presentation.
Dec 09	Clinical data update	Positive	-4.0%	Positive Xywav Phase 4 DUET and real-world data presentations at major meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and corporate updates have often seen negative or muted next-day price reactions.

Recent Company History

Over the past few months, Jazz has highlighted several clinical and corporate milestones. Positive Phase 3 HERIZON-GEA-01 data for Ziihera were followed by a -4.24% reaction on Jan 6, 2026, and investor event announcements on Dec 17, 2025 coincided with a -2.84% move. Earlier, clinical data for Xywav on Dec 9, 2025 saw a -3.95% reaction. In contrast, the appointment of a new Chief Business Officer on Jan 8, 2026 had a modestly positive impact. Today’s earnings date notice fits within this ongoing cadence of updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.  

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. 

About Jazz Pharmaceuticals 
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-tuesday-february-24-2026-302684128.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals (JAZZ) report Q4 and full-year 2025 results?

They will report results after U.S. market close on February 24, 2026, with a webcast at 4:30 p.m. ET. According to the company, management will provide a business and financial update and a replay will be posted on the investor website.

How can investors join the Jazz Pharmaceuticals (JAZZ) earnings webcast on Feb 24, 2026?

Register in advance via the Investors section of Jazz Pharmaceuticals' website or the event registration link provided. According to the company, participants should register at least 15 minutes before the 4:30 p.m. ET webcast to ensure timely connection and can access a replay later on the investor site.

Will Jazz Pharmaceuticals (JAZZ) provide a replay of the Feb 24, 2026 webcast?

Yes. A replay will be available via the Investors section of the Jazz Pharmaceuticals investor website. According to the company, the replay link will be posted at https://investor.jazzpharma.com/investors/events-presentations after the live webcast concludes and archived for later reference.

What time is Jazz Pharmaceuticals' (JAZZ) Feb 24, 2026 webcast and what time zone?

The webcast is scheduled for 4:30 p.m. ET / 9:30 p.m. GMT on February 24, 2026. According to the company, management will discuss fourth quarter and full year 2025 financial results and provide a business update live.

What information will Jazz Pharmaceuticals (JAZZ) cover in the Feb 24, 2026 webcast?

Management will review fourth quarter and full year 2025 financial results and provide a business and financial update. According to the company, the session is intended for investors and analysts and will include a Q&A and replay availability on the investor relations website.